We present evidence that Sp1 dysfunction leads to the blockage of BCR/ABL signaling and CML cell proliferation, thus identifying the Sp1-BCR/ABL axis as a promising target for overcoming aberrant BCR/ABL activity. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.